Part B drug price negotiation now hits hospital buy-and-bill
Medicare's third negotiation cycle is the first to reach physician-administered drugs, which turns a pharmacy benefit story into a provider revenue story for hospitals, infusion centers and oncology practices.
For two cycles, Medicare's drug pricing program was something pharmacy directors and pharma investor relations teams tracked. Part B drug price negotiation changes that. The third cycle of the Medicare Drug Price Negotiation Program, whose selected drug list CMS announced on Jan. 27, 2026, is the first to reach beyond Part D into physician-administered, buy-and-bill medicines. That moves the financial consequence out of the pharmacy benefit and directly onto hospital and clinic income statements.
Why cycle three changes who needs to read the CMS notices
Cycles one and two of the negotiation program touched Part D drugs, where the economics land on plans, pharmacy benefit managers and retail dispensing. Provider organizations had a stake, but an indirect one. Cycle three is different because the selected list extends into Part B, the benefit that covers drugs administered in physician offices, hospital outpatient departments and infusion suites.
CMS followed the January selection announcement with a manufacturer participation fact sheet on March 13, 2026, confirming which drugmakers entered agreements for the cycle. KFF's running explainer on Medicare drug price negotiation, last refreshed March 11, 2026, remains the cleanest neutral reference for the mechanics of timelines, ceiling price calculations and effective dates. Negotiated prices from this cycle are the next scheduled disclosure, which puts the story on a near-term clock rather than a theoretical one.
Part D negotiation was a pharmacy benefit story. Part B negotiation is a provider revenue story.
How ASP-linked reimbursement absorbs a negotiated price
Part B drugs are generally acquired by the provider and reimbursed on a formula linked to average sales price. That structure means the provider carries acquisition cost and collects a payment benchmarked to what the market pays. A negotiated maximum fair price does not simply reduce what Medicare spends. It resets the reference point on both sides of that spread.
The practical questions are sequencing questions. When does a negotiated price begin flowing into the ASP calculation that drives reimbursement, and does a provider's actual acquisition cost move at the same speed? Any lag between those two curves shows up as margin variance on high-volume infusion lines, which for many oncology and rheumatology service lines are among the largest single contributors to outpatient drug revenue. Finance teams that have never had to model an ASP transition for a specific molecule will be doing it for the first time on drugs they cannot easily substitute.
Two pricing regimes, one molecule
The statutory track is not running alone. The administration announced another tranche of voluntary drug pricing agreements on or about Sept. 1, 2026, according to AHA News, and BioPharma Dive reported that mid-cap and biotech-scale manufacturers, not only large caps, joined that round. Separately, PharmExec reported on June 21, 2026 that companies raised list prices, including 16 that had signed agreements to lower prices. Trade policy adds a third variable: 100% tariffs on patented pharmaceuticals with carve-outs took effect in 2026, per a Ropes & Gray client alert dated April 23, 2026, and Axios reported on April 13, 2026 that tariff exposure was pushing biotechs toward pricing deals.
For a provider, that convergence is not abstract. A single Part B molecule can carry a statutory ceiling price, a separate voluntary-agreement price and a tariff-inflated acquisition cost at the same time. Contracting, chargemaster maintenance and claims edit logic all have to hold more than one price for the same NDC and apply the right one to the right payer and patient population.
The 340B overlap most models miss
Covered entities acquire many of these same drugs at 340B prices, and the interaction between a statutory negotiated price and a 340B ceiling price is where financial planning gets genuinely difficult. Programs that have relied on the difference between acquisition cost and ASP-linked reimbursement to fund uncompensated care and specialty pharmacy operations should not assume the spread behaves the same way after a negotiated price enters the ASP series.
This is a modeling exercise, not a policy debate. Health systems that can identify which cycle-three drugs they buy, in what volume, through which acquisition channel, will be able to quantify the exposure. Those that cannot will discover it in a variance report.
What to do before negotiated prices publish
The most useful work is inventory work. Pull the cycle-three selected drug list against internal purchasing data and rank by spend and by margin contribution. Flag every molecule where the organization holds both a 340B acquisition path and a commercial or Medicare Advantage contract, because those are the lines with the most moving parts.
Then bring revenue cycle and health IT into the same room as finance. Chargemaster and contract management systems need to be tested against a scenario in which one product has multiple valid prices and a changing reimbursement benchmark. That test is cheap now. It is expensive as a denial pattern later. Providers modeling cycle-three drugs by volume today will be reacting to a published number, not discovering a structural change in 2028.
